Nicox (LTS:0RCQ) Cash And Cash Equivalents : €10.54 Mil (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Nicox Cash And Cash Equivalents?

Nicox's quarterly cash and cash equivalents declined from Dec. 2023 (€11.26 Mil) to Jun. 2024 (€7.66 Mil) but then increased from Jun. 2024 (€7.66 Mil) to Dec. 2024 (€10.54 Mil).

Nicox's annual cash and cash equivalents declined from Dec. 2022 (€27.08 Mil) to Dec. 2023 (€11.26 Mil) and declined from Dec. 2023 (€11.26 Mil) to Dec. 2024 (€10.54 Mil).

Nicox Cash And Cash Equivalents Historical Data

The historical data trend for Nicox's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Cash And Cash Equivalents Chart

Nicox Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

47.20

41.97

27.08

11.26

10.54

Nicox Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															27.08	19.01	11.26	7.66	10.54

Nicox Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nicox (LTS:0RCQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nicox Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nicox's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines